Cargando…

Effect of TOP2A and ERCC1 gene polymorphisms on the efficacy and toxicity of cisplatin and etoposide-based chemotherapy in small cell lung cancer patients

INTRODUCTION: The main treatment regimen for small cell lung cancer (SCLC) involves platinum-based chemotherapy (cisplatin or carboplatin) and etoposide. Single nucleotide polymorphisms (SNPs) in TOP2A and ERCC1 genes were tested as prognostic and predictive factors in non-small cell lung cancer (NS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nicoś, Marcin, Rolska-Kopińska, Anna, Krawczyk, Paweł, Grenda, Anna, Bożyk, Aleksandra, Szczyrek, Michał, Milanowski, Janusz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2020
Materias:	Basic Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7959040/ https://www.ncbi.nlm.nih.gov/pubmed/33747282 http://dx.doi.org/10.5114/aoms.2020.92572

Ejemplares similares

Promoter polymorphisms of TOP2A and ERCC1 genes as predictive factors for chemotherapy in non‐small cell lung cancer patients
por: Grenda, Anna, et al.
Publicado: (2019)

Attempting to Identify Bacterial Allies in Immunotherapy of NSCLC Patients
por: Grenda, Anna, et al.
Publicado: (2022)

Presence of Akkermansiaceae in gut microbiome and immunotherapy effectiveness in patients with advanced non-small cell lung cancer
por: Grenda, Anna, et al.
Publicado: (2022)

Tumor Microenvironment—A Short Review of Cellular and Interaction Diversity
por: Bożyk, Aleksandra, et al.
Publicado: (2022)

MET Gene Dysregulation as a Promising Therapeutic Target in Lung Cancer—A Review
por: Terlecka, Paulina, et al.
Publicado: (2021)

Methylation of DROSHA and DICER as a Biomarker for the Detection of Lung Cancer
por: Szczyrek, Michał, et al.
Publicado: (2021)

Beyond PD-L1 Markers for Lung Cancer Immunotherapy
por: Wojas-Krawczyk, Kamila, et al.
Publicado: (2019)

Immunohistochemical assays incorporating SP142 and 22C3 monoclonal antibodies for detection of PD-L1 expression in NSCLC patients with known status of EGFR and ALK genes
por: Krawczyk, Paweł, et al.
Publicado: (2017)

Letter to the editor concerning first-line therapy with afatinib – an irreversible EGFR TKI and overall survival of NSCLC patients with EGFR gene mutations
por: Krawczyk, Paweł, et al.
Publicado: (2015)

The Role of Intratumor Heterogeneity in the Response of Metastatic Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors
por: Nicoś, Marcin, et al.
Publicado: (2020)

Interactions between Dietary Micronutrients, Composition of the Microbiome and Efficacy of Immunotherapy in Cancer Patients
por: Frąk, Małgorzata, et al.
Publicado: (2022)

Predictive Value of Single Nucleotide Polymorphisms of ERCC1, XPA, XPC, XPD and XPG Genes, Involved in NER Mechanism in Patients with Advanced NSCLC Treated with Cisplatin and Gemcitabine
por: Mlak, Radosław, et al.
Publicado: (2018)

Polymorphisms in the Gene Encoding Caspase 8 May Predict the Response to First-Line Platinum-Based Chemotherapy in Locally Advanced or Advanced Non-Small-Cell Lung Cancer
por: Szczyrek, Michał, et al.
Publicado: (2021)

HER2 gene assessment in liquid biopsy of gastric and esophagogastric junction cancer patients qualified for surgery
por: Grenda, Anna, et al.
Publicado: (2020)

Diet, Microbiome, and Cancer Immunotherapy—A Comprehensive Review
por: Szczyrek, Michał, et al.
Publicado: (2021)

Prevalence of NRAS, PTEN and AKT1 gene mutations in the central nervous system metastases of non-small cell lung cancer
por: Nicoś, Marcin, et al.
Publicado: (2017)

Efficacy of Dabrafenib and Trametinib in a Patient with Squamous-Cell Carcinoma, with Mutation p.D594G in BRAF and p.R461* in NF1 Genes—A Case Report with Literature Review
por: Grenda, Anna, et al.
Publicado: (2023)

The impact of ACE gene polymorphism on the incidence and phenotype of sarcoidosis in rural and urban settings
por: Kieszko, Robert, et al.
Publicado: (2015)

Polymorphisms of Genes Encoding Multidrug Resistance Proteins as a Predictive Factor for Second-Line Docetaxel Therapy in Advanced Non-small Cell Lung Cancer
por: Szczyrek, Michał, et al.
Publicado: (2016)

Correlation between KRAS, NRAS and BRAF mutations and tumor localizations in patients with primary and metastatic colorectal cancer
por: Bożyk, Aleksandra, et al.
Publicado: (2021)

The Overview of Perspectives of Clinical Application of Liquid Biopsy in Non-Small-Cell Lung Cancer
por: Bożyk, Aleksandra, et al.
Publicado: (2022)

Evaluation of ALK gene rearrangement in central nervous system metastases of non-small-cell lung cancer using two-step RT-PCR technique
por: Nicoś, M., et al.
Publicado: (2017)

Breaking the ‘Undruggable’ Barrier: Anti-PD-1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer Patients with KRAS Mutations—A Comprehensive Review and Description of Single Site Experience
por: Chmielewska, Izabela, et al.
Publicado: (2023)

Polymorphism of Baculoviral Inhibitor of Apoptosis Repeat-Containing 5 (BIRC5) Can Be Associated with Clinical Outcome of Non-Small Cell Lung Cancer
por: Szczyrek, Michał, et al.
Publicado: (2022)

Impact of I/D polymorphism of ACE gene on risk of development and course of chronic obstructive pulmonary disease
por: Mlak, Radosław, et al.
Publicado: (2016)

Mechanisms of resistance to reversible inhibitors of EGFR tyrosine kinase in non-small cell lung cancer
por: Krawczyk, Paweł, et al.
Publicado: (2012)

Analysis of KRAS and BRAF genes mutation in the central nervous system metastases of non-small cell lung cancer
por: Nicoś, Marcin, et al.
Publicado: (2015)

Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients
por: Krawczyk, Paweł, et al.
Publicado: (2014)

Pleural Neoplasms—What Could MRI Change?
por: Szczyrek, Michał, et al.
Publicado: (2023)

Sensitive methods for detection of the S768R substitution in exon 18 of the DDR2 gene in patients with central nervous system metastases of non-small cell lung cancer
por: Nicoś, Marcin, et al.
Publicado: (2014)

An Exceptionally Favorable Response to Etoposide and Cisplatin
por: Valecha, Gautam, et al.
Publicado: (2015)

Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement
por: Krawczyk, Paweł, et al.
Publicado: (2021)

The Role of the Selected miRNAs as Diagnostic, Predictive and Prognostic Markers in Non-Small-Cell Lung Cancer
por: Szczyrek, Michał, et al.
Publicado: (2022)

The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients
por: Obiedat, Hadeel, et al.
Publicado: (2018)

First line combination chemotherapy with cisplatin and etoposide in advanced ovarian cancer.
por: Athanassiou, A. E., et al.
Publicado: (1989)

Feasibility of combination chemotherapy with cisplatin and etoposide for haemodialysis patients with lung cancer
por: Watanabe, R, et al.
Publicado: (2003)

Botulinum toxin in cancer therapy—current perspectives and limitations
por: Grenda, Tomasz, et al.
Publicado: (2021)

Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases
por: Nicoś, Marcin, et al.
Publicado: (2022)

Comparison of Ifosfamide, Carboplatin and Etoposide versus Etoposide, Steroid, and Cytarabine Cisplatin as Salvage Chemotherapy in Patients with Refractory or Relapsed Hodgkin's lymphoma
por: Mehrzad, Valiollah, et al.
Publicado: (2017)

A Phase III Randomized Study Comparing a Chemotherapy with Cisplatin and Etoposide to a Etoposide Regimen without Cisplatin for Patients with Extensive Small-Cell Lung Cancer
por: Berghmans, Thierry, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_vfulpo0e1ph75bvjhhft6icoe3